TITLE

FDA Questioned by Other Feds on High-Risk Devices

AUTHOR(S)
Reed, Vita
PUB. DATE
April 2011
SOURCE
Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient proof of safety.
ACCESSION #
60463111

 

Related Articles

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • DRUG SAFETY: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed.  // GAO Reports;12/9/2009, preceding p1 

    The article discusses the findings of the U.S. Government Accountability Office (GAO) on the oversight of postmarket drug safety by the Food and Drug Administration (FDA). GAO claims that FDA has started to address concerns in its postmarket drug safety management. GAO also admires FDA's move to...

  • FOOD SAFETY: FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS). Shames, Lisa // GAO Reports;3/5/2010, preceding p1 

    The article examines the oversight of the U.S. Food and Drug Administration on generally recognized as safe (GRAS) substances, by the Government Accountability Office (GAO). It was found that its oversight process does not ensure the safety of GRAS determinations. The agency does not issue...

  • New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49. Aronovitz, Leslie G. // GAO Reports;12/19/2006, p1 

    Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and...

  • Medical Devices: Status of FDA's Program for Inspections by Accredited Organizations: GAO-07-157. Crosse, Marcia // GAO Reports;1/5/2007, p1 

    The Food and Drug Administration (FDA) inspects domestic and foreign establishments where U.S.-marketed medical devices are manufactured to assess compliance with FDA's quality system requirements for ensuring good manufacturing practices and other applicable requirements. The Medical Device...

  • Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process: GAO-07-599T.  // GAO Reports;3/22/2007, p1 

    GAO was asked to testify on the effectiveness of the Food and Drug Administration's (FDA) postmarket decision-making process. This testimony is based on Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process, GAO-06-402 (March 31, 2006). The report focused on...

  • Drug Safety: GAO-08-701T.  // GAO Reports;4/22/2008, p1 

    The Food and Drug Administration (FDA) is responsible for overseeing the safety and effectiveness of human drugs that are marketed in the United States, whether they are manufactured in foreign or domestic establishments. FDA inspects foreign establishments to ensure that they meet the same...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics